Hologic (NSDQ:HOLX) today announced that it has completed its $795 million acquisition of diagnostic developer Mobidiag Oy.
France-based Mobidiag develops PCR-based tests for acute care conditions, including gastrointestinal and respiratory infections, antimicrobial resistance management and healthcare-associated infections. Its Amplidiag and Novodiag platforms can deliver results in 50 minutes to two hours.
Marlborough, Mass.-based Hologic announced the deal in April when it said it would make a cash payment of approximately $714 million for Mobidiag’s equity and net debt of approximately $81 million.
“Closing the acquisition of Mobidiag enables us to become a broader, more diversified global diagnostics leader,” Jan Verstreken, international president at Hologic, said in a news release. “Together, we can accelerate development and adoption of Mobidiag’s innovative products globally and drive Hologic’s growth.”
Hologic previously said that it would invest in assay development to drive Novodiag’s growth.
The Mobidiag purchase is the fourth acquisition deal for Hologic this year. It bought Somatex for $64 million in January, Biotheranostics for $230 million in February and Diagenode for $159 million in March.